Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

This study has been completed.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Bristol-Myers Squibb
Information provided by (Responsible Party):
Andrew X. Zhu, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00142428
First received: August 31, 2005
Last updated: March 16, 2014
Last verified: March 2014

August 31, 2005
March 16, 2014
January 2005
October 2005   (final data collection date for primary outcome measure)
Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To assess the progression free survival in patients with unresectable or metastatic hepatocellular carcinoma.
Complete list of historical versions of study NCT00142428 on ClinicalTrials.gov Archive Site
  • Number of patients with adverse events [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Overall Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Objective Response Rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To evaluate the side effects of cetuximab in this population as well as the response rate, duration of response and overall survival of patients.
Not Provided
Not Provided
 
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
A Phase II Study of Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

The main purpose of this study is to begin to collect information and to try to learn whether or not cetuximab works in treating patients with unresectable or metastatic hepatocellular carcinoma.

The first step in this study is to examine the tumor biopsy (previously collected) and determine whether or not it is epidermal growth factor receptor (EGFR) positive or EGFR negative. Both EGFR positive and EGFR negative patients can participate in this study because at this time it is not known whether having a negative or positive receptor makes a difference in how the study drug works on the tumor. By knowing if the tumor is EGFR positive or negative, we will be able to see if there is a difference in the way the tumor responds to cetuximab.

Patients will receive cetuximab intravenously once weekly for 6 weeks. Each 6-week period is one cycle of treatment. The first dose of cetuximab is larger than the following doses.

For the first clinic visit the patient's blood pressure, temperature, breathing and heart rate will be taken before, during, at the end, and one-hour after the cetuximab has been administered. For each visit after that, blood pressure, temperature, breathing and heart rate will be taken before and after cetuximab has been administered.

Before each administration of cetuximab, diphenhydramine will also be administered to decrease the chances of an allergic or hypersensitivity reaction.

The following tests and procedures will be performed at weeks 1, 3 and 5 during each 6-week cycle of treatments as well as at the end of study treatment: physical exam, vital signs, medical history and blood work. At the end of each 6-week cycle a CT and/or MRI will be performed to measure the tumor size.

Long-term follow-up will include physical exams and bloodwork every 6 months.

Patients will remain on cetuximab as long as there is no disease progression or intolerable side effects.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatocellular Carcinoma
Drug: Cetuximab
The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
Experimental: Cetuximab
The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
Intervention: Drug: Cetuximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
October 2008
October 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Unresectable or metastatic hepatocellular carcinoma
  • Measurable tumor
  • Adequate hepatic function: total bilirubin < 3.0mg/dl; AST < 7 x upper limit of normal (ULN).
  • Adequate renal function: serum creatinine < 2.0mg/dl
  • Adequate bone marrow function: absolute neutrophil count (ANC) > 1,000/mm3; platelets > 75,000/mm3.
  • 0-2 prior systemic chemotherapy regimens for hepatocellular carcinoma
  • 18 years of age and older
  • ECOG performance status of 0-2
  • Life expectancy > 12 weeks

Exclusion Criteria:

  • Surgery, excluding prior diagnostic biopsy or venous access device placement, within 28 days of study entry
  • Uncontrolled serious medical or psychiatric illness
  • Irradiation or chemotherapy for disease within 28 days of study entry
  • Clinically apparent central nervous system metastases or carcinomatous meningitis
  • Received an investigational agent within 30 days
  • Cancer of the Liver Italian Program (CLIP) score > 3
  • Acute hepatitis
  • Active or uncontrolled infection
  • Significant history of cardiac disease
  • Prior cetuximab or other therapy which specifically and directly targets the EGFR pathway
  • Prior allergic reaction to chimerized or murine monoclonal antibody therapy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00142428
04-347
Yes
Andrew X. Zhu, MD, Massachusetts General Hospital
Massachusetts General Hospital
  • Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
Principal Investigator: Andrew X. Zhu, MD Massachusetts General Hospital
Massachusetts General Hospital
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP